117 results
6-K
EX-99.1
ALVO
Alvotech
22 May 24
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
6:30am
including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
9:00am
, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
8:41am
released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability … including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future
6-K
EX-99.1
ALVO
Alvotech
30 Apr 24
Current report (foreign)
8:00am
including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future
6-K
EX-99.1
ALVO
Alvotech
25 Apr 24
Current report (foreign)
12:36pm
, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review
6-K
EX-99.1
i49570mbrie0s
19 Apr 24
Current report (foreign)
8:05am
6-K
EX-99.1
7jy9cs 87v8dkpnjq9uk
16 Apr 24
Current report (foreign)
6:30pm
6-K
EX-99.2
r185w22yd xh
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
6-K
EX-99.1
jtz5q
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
6-K
EX-99.3
g9crk4
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
6-K
EX-99.1
1ievzthifme
26 Feb 24
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
7:00am
6-K
EX-99.1
s5hs32y
23 Feb 24
Current report (foreign)
8:39pm
6-K
EX-99.1
rmz 1br99palgts3g
29 Jan 24
Current report (foreign)
7:00am
6-K
EX-99.1
up9kq6xgj4e2wst1qhyd
10 Jan 24
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
7:00am
6-K
EX-99.1
u4j11905 av5n
3 Jan 24
Current report (foreign)
2:28pm
6-K/A
EX-99.1
u1r04efu01
30 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
9:19am
6-K
EX-99.1
ula6s6rlpznvf
29 Nov 23
Current report (foreign)
7:00am
6-K
EX-99.1
9caobsmy 85q88dqjf
29 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
7:00am
6-K
EX-99.1
4mzwoz cz
13 Nov 23
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
6:15am